key: cord-0775149-cmc5c1p6
authors: Bertuzzi, Alexia F.; Ciccarelli, Michele; Marrari, Andrea; Gennaro, Nicolò; Dipasquale, Andrea; Giordano, Laura; Cariboni, Umberto; Quagliuolo, Vittorio Lorenzo; Alloisio, Marco; Santoro, Armando
title: Impact of active cancer on COVID-19 survival: a matched-analysis on 557 consecutive patients at an Academic Hospital in Lombardy, Italy
date: 2021-05-11
journal: Br J Cancer
DOI: 10.1038/s41416-021-01396-9
sha: ca079122b200c8a6e726d62208cfc04339353925
doc_id: 775149
cord_uid: cmc5c1p6

BACKGROUND: The impact of active cancer in COVID-19 patients is poorly defined; however, most studies showed a poorer outcome in cancer patients compared to the general population. METHODS: We analysed clinical data from 557 consecutive COVID-19 patients. Uni-multivariable analysis was performed to identify prognostic factors of COVID-19 survival; propensity score matching was used to estimate the impact of cancer. RESULTS: Of 557 consecutive COVID-19 patients, 46 had active cancer (8%). Comorbidities included diabetes (n = 137, 25%), hypertension (n = 284, 51%), coronary artery disease (n = 114, 20%) and dyslipidaemia (n = 122, 22%). Oncologic patients were older (mean age 71 vs 65, p = 0.012), more often smokers (20% vs 8%, p = 0.009), with higher neutrophil-to-lymphocyte ratio (13.3 vs 8.2, p = 0.046). Fatality rate was 50% (CI 95%: 34.9;65.1) in cancer patients and 20.2% (CI 95%: 16.8;23.9) in the non-oncologic population. Multivariable analysis showed active cancer (HR(active): 2.26, p = 0.001), age (HR(age>65years): 1.08, p < 0.001), as well as lactate dehydrogenase (HR(LDH>248mU/mL): 2.42, p = 0.007), PaO2/FiO2 (HR(continuous): 1.00, p < 0.001), procalcitonin (HR(PCT>0.5ng/mL): 2.21, p < 0.001), coronary artery disease (HR(yes): 1.67, p = 0.010), cigarette smoking (HR(yes): 1.65, p = 0.041) to be independent statistically significant predictors of outcome. Propensity score matching showed a 1.92× risk of death in active cancer patients compared to non-oncologic patients (p = 0.013), adjusted for ICU-related bias. We observed a median OS of 14 days for cancer patients vs 35 days for other patients. CONCLUSION: A near-doubled death rate between cancer and non-cancer COVID-19 patients was reported. Active cancer has a negative impact on clinical outcome regardless of pre-existing clinical comorbidities.

Since the beginning of the COVID-19 pandemic, cancer patients have been regarded as a vulnerable population. [1] [2] [3] [4] Early data reported a near two-fold risk of Sars-CoV-2 infection, a complicated course of infection and a higher fatality rate compared to non-oncologic patients. [4] [5] [6] [7] [8] However, detailed data on the extent of the oncologic disease and anti-cancer therapies at Sars-CoV-2 diagnosis were often scant. Later analyses suggested a downsised risk of infection in cancer patients. We previously reported the experience of a referral Cancer Center in the epicentre of the Italian outbreak, with only 17 cases of Sars-CoV-2 being diagnosed among 1267 cancer patients on active medical treatment. 9 In line with initial clinical suggestions, we registered a higher COVID-19 fatality in oncologic patients compared to the general population. [10] [11] [12] In this uncertain scenario, major oncological societies released position papers recommending extreme caution in the management of cancer treatment, focusing on the undefined risk of a medical therapy impacting on the immune system. 3, [13] [14] [15] The worldwide spread of Sars-CoV-2 infection imposed a tough challenge for medical oncologists bearing the responsibility to treat cancer, an equally fatal disease. [16] [17] [18] [19] [20] [21] Consequently, efforts have been conducted to optimise cancer therapy during the pandemic and to better identify the features of poor outcome of the infection in cancer patients. 22, 23 Some published studies analysed demographic and clinical characteristics in this subgroup of patients detailing comorbidities, specific laboratory findings as well as radiological imaging at Sars-CoV-2 diagnosis. 24, 25 As a Cancer and COVID-19 referral centre, we also collected the aforementioned variables on the whole population of infected patients admitted in our Institution during the most intense period of the pandemic. We retrospectively analysed in a multivariate model, and confirmed by a propensity score, the weight of some of the most important aspects recognised as a risk factor for Sars-CoV-2 outcome, focusing on active cancer. 12, 26, 27 

We retrospectively reviewed the medical records of all consecutive adult patients admitted for COVID-19 at our Institution (a tertiary cancer centre with 662 beds, including 42 ICU beds) between February 27 and May 20, 2020. The diagnosis of Sars-CoV-2 infection was confirmed by a reverse-transcriptase polymerase chain reaction (RT-PCR) of nasopharyngeal swab or bronchoalveolar lavage (BAL). We collected data on demographics, smoking habits and comorbidities, including coronary artery disease (CAD), onco-haematologic disease, diabetes and hypertension. We collected also the clinical characteristics of Sars-CoV-2 at presentation, the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) laboratory findings including full blood count (FBC), inflammatory indexes (procalcitonin, PCT, CRP, ferritin, IL-6), lactate dehydrogenase (LDH) and radiological CT findings. We analysed SARS-CoV-2 active cancer patients focusing on the type of malignancy (solid tumour vs haematologic disease), the diagnosis (lung cancer, genitourinary-GU cancer, gastrointestinal-GI cancer, breast cancer and other)), the extent (localised vs metastatic) and the status of disease at the COVID-19 diagnosis, i.e. progressive disease (PD) vs non-PD (CR/PR/ SD/NED). Active cancer was defined by the presence of localised or metastatic disease at the time of the viral infection, despite the received oncological treatment. Patients undergoing radical surgery or radical radio-chemotherapy within 4 weeks from COVID-19 diagnosis were also included in the analysis. Conversely, patients with a history of cancer or on adjuvant hormonal treatment were not considered in the cancer subgroup. Surrogate endpoints for COVID-19 survival included the length of hospitalisation, the ICU admission and the in-hospital fatality rate. The absence of prospective informed consent was waived by the Ethics Committee due to the emergency situation of the clinical scenario of the current pandemic.

Demographic and clinical characteristics were summarised as number and percentage or as median and range. Differences in distribution were estimated using the Chi-square or the Fisher exact test (when appropriate). Patients survival was calculated from the hospitalisation until death or discharge. Survival curves were generated using the Kaplan-Meier method. Median follow-up was estimated using the inverse Kaplan-Meier method. Differences between groups were evaluated using the log-rank test. The Cox proportional hazard regression model was used to calculate the hazard ratios (HRs) and their 95% confidence intervals (CI) in univariate and multivariate analysis. ICU was included in the model as a time-dependent variable starting from the first day of ICU admission. A propensity score matching was performed to estimate the effect of cancer by accounting for the covariates statistically significant in the multivariable model. For each cancer patient, four comparable patients were selected in the non-cancer population (1:4 ratio). All the reported p-values were two-sided. All analyses were carried out with the SAS software v. 9.4.

We reported on 557 consecutive COVID-19 patients admitted at our Institution between February 27 and May 20, 2020, of whom 46 had active cancer (8%). Demographics, clinical and laboratory findings of COVID-19 patients are reported in Table 1 . Most compared to 35 days for other patients (Fig. 1) . Considering the cancer cohort, we did not observe any difference between solid and haematologic tumours (HR 1.04, CI 95%: 0.41;2.65, p = 0.931, Fig. 2a) . Noteworthy, lung cancer patients showed a poor prognosis compared to other cancer diagnosis (Fig. 2b) 1) . We did not report any differences in outcome between localised and metastatic disease (HR: 0.8; CI 95%: 0.31;2.08, p = 0.649, Fig. 2c ) but, considering disease status at COVID-19 diagnosis, we reported a significantly worse COVID-19 outcome in patients with progressive disease (PD) compared to non-PD patients (HR: 2.931, CI 95% 1.2;7.14, p = 0.018, Fig. 2d ). Extent of disease and delivered treatment are reported in Table 5 for each tumour type.

In our retrospective analysis, we have reported that both the epidemiology and clinical presentation of COVID-19 in active cancer patients in Italy are similar to the non-cancer population This notwithstanding, we observed how the natural course of the COVID-19, as well as the final outcome, are significantly worse in cancer patients, resulting in an almost double fatality rate (HR: 1.92, propensity score result). Working at an Institution extensively involved in the COVID-19 emergency, we had the opportunity to evaluate a large number of admitted patients, collecting detailed clinical, laboratory and radiological data, including comorbidities such as cancer and related treatment. 9 In the current analysis, the demographics and clinical characteristics of cancer and noncancer patients were similar including BMI. 28 A male predominance in COVID-19, possibly explained by differences in innate and adaptive immunity, has been confirmed. 29 At the time of COVID-19 diagnosis, the clinical presentation was similar among the two cohorts of patients. Unexpectedly, the respiratory impairment evaluated through PaO2/FiO2, as well as chest CT scan performed in the Emergency Department did not show any significant differences. As we had previously published, 9 active cancer and relative treatments, including chemotherapy, immunotherapy and targeted therapies, did not result in an increased risk of Sars-CoV-2 infection. 9 The lack of standardised criteria to define active cancer patients might have been responsible for the initial worries regarding the reported high incidence of cancer patients among Sars-CoV-2 infected individuals. 30, 31 A detailed analysis of published case-series showed most of them were likely patients with a history of cancer, rather than with active cancer. Even if the risk for Sars-CoV-2 infection and the clinical presentation of COVID-19 are similar, it does result in a double mortality rate in cancer patients compared to non-cancer patients in a multivariable analysis (HR active : 2.21). Unexpectedly, we did not notice any differences between solid and haematologic cancers. However, focusing on the histological diagnosis, we observed that only few patients were affected by aggressive blood diseases (e.g. AML or NHL) rather than chronic, indolent disease that would arguably affect the course of the infection. Several efforts have been made to decipher the negative influence of cancer on COVID-19 outcome. Our results confirm the higher mortality rate among cancer patients compared to nononcological populations. 6, [10] [11] [12] 32 In stark contrast with such reports, a matched cohort study from the Presbyterian Hospital (New York, USA) reported similar outcomes in cancer and noncancer COVID-19 patients. Unlike previous studies, the authors included in the cancer subgroup, either patients who received active cancer treatment and patients on follow-up who received the last oncologic therapy up to 6 months before the admission for COVID-19. We adopted more stringent criteria including in the cancer cohort only those patients with localised or metastatic disease who received diagnosis or therapy within 4 weeks before the admission for COVID-19. Several factors could play a role in the fatal course of COVID-19 in patients with active cancer. First of all, cancer-related inflammation, as well as the associated One patient underwent immuno-chemotherapy. c Two patients had head&neck cancer, one had glioblastoma, one had neuroendocrine tumour and one had unknown primary tumour.

prothrombotic status typically related to uncontrolled solid or haematologic cancer growth, could be responsible for the unfavourable prognosis in hospitalised COVID-19 patients. [33] [34] [35] We suspected also a higher incidence of bacterial co-infection in the oncologic cohort, with a potential detrimental effect on outcome. Still, our study did not support this hypothesis as PCT values were comparable among the two groups. In line with our findings, a recent meta-analysis on 3834 patients showed a low proportion of COVID-19 patients having bacterial co-infection. 36 Our study has some limitations. We acknowledge that ascribing the ultimate cause of death in cancer patients with COVID-19 is challenging. However, our results highlight that patients with newly diagnosed uncontrolled cancer, as well as progressive disease, are more likely to show a poor prognosis in case of COVID-19 infection, which may be related to an impaired immunological response. A further potential bias might be represented by the availability of intensive care in the ICU in a scenario of limited resources. Despite the low number of events, we proved by the propensity score analysis that admission to the ICU did not account for differences in outcome between the two cohorts of patients. Finally, the mono-institutional nature of our study prevented us from recruiting a large number of patients, thus limiting our analysis, especially in some specific histiotypes (e.g. aggressive blood disease). In conclusion, despite a comparable clinical presentation, we report a near two-fold increase in death rate between cancer and non-cancer COVID-19 patients admitted at a tertiary referral Italian hospital. Our data suggest uncontrolled cancer diagnosis to independently impact on clinical outcome regardless of other clinical characteristics including preexisting comorbidities. To date, the understanding of the natural course of COVID-19 in active cancer patients is limited, and requires further cooperative efforts to be unfolded. Considering the vulnerable status of patients with active cancer in the current pandemic, state-ofthe art cancer care should guarantee the continuity of treatment along with a direct engagement of multidisciplinary stakeholders to meet patients' needs. 37, 38 

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan

A war on two fronts: cancer care in the time of COVID-19

Risk of COVID-19 for patients with cancer

COVID-19 and cancer: what we know so far

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis

Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study

Managing patients with cancer during the COVID-19 pandemic: frontline experience from Wuhan

Low incidence of SARS-CoV-2 in patients with solid tumours on active treatment: an observational study at a Tertiary Cancer Centre in Lombardy

and Cancer: a Comprehensive Review

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

The risk and prognosis of COVID-19 infection in cancer patients: a systematic review and meta-analysis

ASCO Statement on Novel Coronavirus (COVID-19). ASCO Annual Meeting

COVID-19 and Cancer

Cancer guidelines during the COVID-19 pandemic

Cancer prevales on COVID-19: To maintain high quality standard concerning diagnosis and oncological care even during a pandemic

Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective

The impact of the COVID-19 pandemic on cancer patients

Quality of life of cancer patients during coronavirus disease (COVID-19) pandemic

The impact of the COVID-19 pandemic on cancer care

Cancer treatment during the coronavirus disease 2019 pandemic: do not postpone, do it!

COVID-19 infection in cancer patients: early observations and unanswered questions

Cancer and COVID-19: what do we really know?

Cancer and SARS-CoV-2 infection: diagnostic and therapeutic challenges

A systematic review and meta-analysis of cancer patients affected by a novel coronavirus

Cancer increases risk of inhospital death from COVID-19 in persons <65 years and those not in complete remission

The impact of COVID-19 on cancer risk and treatment

Obesity in patients with COVID-19: a systematic review and meta-analysis

Impact of active cancer on COVID-19 survival: a matched-analysis on 557

Sex differences in immune responses that underlie COVID-19 disease outcomes

Cancer patients and risk of mortality for COVID-19

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region

Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Singhania, G. Current overview on hypercoagulability in COVID-19

The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management

Co-infections in people with COVID-19: a systematic review and meta-analysis

The blurred line between the art and science of medicine

Engaging multidisciplinary stakeholders to drive shared decision-making in oncology

Impact of active cancer on COVID-19 survival: a matched-analysis on 557

Not applicable. 

Ethics approval and consent to participate Ethics approval was provided by the local ethics committee of Humanitas Clinical and Research Center; the study was performed in accordance with the Declaration of Helsinki. Consent to participate was obtained from the patients involved in the study.Consent to publish Consent for publication have be obtained from the patients involved in the study.Data availability The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Funding information The authors received no specific funding for this work.The online version contains supplementary material available at https://doi.org/ 10.1038/s41416-021-01396-9.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.